https://mindmedicinelaw.com/briefing/big-data-in-psychiatric-and-psychedelic-research-opportunities-and-cautions-20261001-45756The Psychedelic Journalen2026-10-01T15:07:31.013138+00:00Big Data in Psychiatric and Psychedelic Research: Opportunities and Cautionsbig data, psychiatric research, psychedelic science, clinical trials, genomics, neuroimaging, methodological rigor, data quality, regulatory policy, artificial intelligencehttps://mindmedicinelaw.com/briefing/dea-proposes-stricter-reporting-for-suspicious-psychedelic-orders-20261001-45697The Psychedelic Journalen2026-10-01T15:06:09.908087+00:00DEA Proposes Stricter Reporting for Suspicious Psychedelic Ordersdea, suspicious order reporting, controlled substances, psychedelic research, compliance, clinical trials, supply chain, regulatory risk, schedule i substanceshttps://mindmedicinelaw.com/briefing/dea-proposes-365-day-reexport-window-for-controlled-substances-20261001-45690The Psychedelic Journalen2026-10-01T15:05:54.295992+00:00DEA Proposes 365-Day Reexport Window for Controlled Substancesdea, reexportation period, controlled substances, psychedelic research, international supply chain, regulatory compliance, clinical trials, policy change, pharmaceutical logisticshttps://mindmedicinelaw.com/briefing/neuroscience-based-psychiatry-rethinking-diagnosis-for-psychedelic-therapies-20260930-45745The Psychedelic Journalen2026-10-01T15:06:28.032240+00:00Neuroscience-Based Psychiatry: Rethinking Diagnosis for Psychedelic Therapiespsychiatric diagnosis, neuroscience, clinical brain profiling, psychedelic therapies, brain network dynamics, plasticity, biomarker-driven psychiatry, clinical trials, regulatory sciencehttps://mindmedicinelaw.com/briefing/psilocybin-adverse-effects-in-cyclothymia-clinical-and-policy-lessons-20260930-45650The Psychedelic Journalen2026-09-30T22:07:05.261616+00:00Psilocybin Adverse Effects in Cyclothymia: Clinical and Policy Lessonspsilocybin, cyclothymia, mood disorders, adverse effects, clinical trial screening, psychedelic research, risk management, policy implications, mental healthhttps://mindmedicinelaw.com/briefing/va-launches-psilocybin-study-for-veterans-policy-and-research-implications-in-th-20260930-45662The Psychedelic Journalen2026-09-30T22:06:54.084970+00:00VA Launches Psilocybin Study for Veterans: Policy and Research Implications in the USva psilocybin study, veterans mental health, psychedelic research policy, independent research funding, federal clinical trials, ptsd depression treatment, schedule i regulation, data transparency, us psychedelic sciencehttps://mindmedicinelaw.com/briefing/dea-schedule-i-proposal-for-fda-breakthrough-postpartum-depression-drug-20260930-45660The Psychedelic Journalen2026-09-30T22:05:06.687456+00:00DEA Schedule I Proposal for FDA Breakthrough Postpartum Depression Drugdea schedule i, postpartum depression, breakthrough therapy, fda, psychedelic research, clinical trials, controlled substances act, drug policy, research barriers, mental health innovationhttps://mindmedicinelaw.com/briefing/psilocybin-clinical-trial-for-depression-in-lung-cancer-patients-us-2026-20260930-45500The Psychedelic Journalen2026-09-30T15:04:30.513468+00:00Psilocybin Clinical Trial for Depression in Lung Cancer Patients (US, 2026)psilocybin, lung cancer, depression, clinical trial, oncology, palliative care, psychedelic therapy, FDA, insurance coverage, mental healthhttps://mindmedicinelaw.com/briefing/psychedelic-branding-vs-local-narrative-mad-honey-in-nepal-20260929-45715The Psychedelic Journalen2026-10-01T15:07:49.500877+00:00Psychedelic Branding vs. Local Narrative: Mad Honey in Nepalmad honey, psychedelic discourse, Nepal, local narrative, grayanotoxins, ethnography, cultural legitimacy, psychedelic industry, policy implications, traditional medicinehttps://mindmedicinelaw.com/briefing/evaluating-psychedelic-harm-reduction-new-framework-for-event-settings-20260929-45551The Psychedelic Journalen2026-09-30T22:05:38.818260+00:00Evaluating Psychedelic Harm Reduction: New Framework for Event Settingspsychedelic harm reduction, event health infrastructure, zendo project, peer support, public health policy, mixed-methods evaluation, non-clinical psychedelic use, framework development, safety at festivals, policy implicationshttps://mindmedicinelaw.com/briefing/ketamine-vs-ect-for-severe-depression-meta-analysis-shifts-clinical-debate-20260929-45595The Psychedelic Journalen2026-09-30T22:05:22.277062+00:00Ketamine vs ECT for Severe Depression: Meta-Analysis Shifts Clinical Debateketamine, electroconvulsive therapy, treatment-resistant depression, meta-analysis, neurocognitive outcomes, clinical guidelines, psychiatry, policy, payer decisionshttps://mindmedicinelaw.com/briefing/calgary-launches-psychedelic-ptsd-trial-for-partner-violence-survivors-20260929-45400The Psychedelic Journalen2026-09-29T22:04:40.494825+00:00Calgary Launches Psychedelic PTSD Trial for Partner Violence Survivorscalgary psychedelic trial, ptsd partner violence, canada mental health policy, psychedelic-assisted therapy, trauma research, clinical trial canada, health canada special access program, ethical considerations psychedelics, public health trauma, complex ptsd treatmenthttps://mindmedicinelaw.com/briefing/meta-analysis-psychedelics-anti-inflammatory-effects-and-policy-implications-20260928-45800The Psychedelic Journalen2026-10-01T15:05:31.608526+00:00Meta-Analysis: Psychedelics’ Anti-Inflammatory Effects and Policy Implicationspsychedelics, anti-inflammatory, immunomodulation, serotonergic, clinical trials, policy implications, autoimmune disease, FDA, biomarkers, public healthhttps://mindmedicinelaw.com/briefing/emergency-management-of-emerging-synthetic-drug-intoxications-20260928-45553The Psychedelic Journalen2026-09-30T22:07:16.571963+00:00Emergency Management of Emerging Synthetic Drug Intoxicationsemerging synthetic drugs, emergency medicine, toxidrome recognition, psychiatric complications, synthetic cannabinoids, synthetic cathinones, nitazenes, xylazine, clinical toxicology, integrated carehttps://mindmedicinelaw.com/briefing/systematic-review-anti-inflammatory-effects-of-psychedelics-in-preclinical-model-20260928-45584The Psychedelic Journalen2026-09-30T22:06:25.787984+00:00Systematic Review: Anti-Inflammatory Effects of Psychedelics in Preclinical Modelspsychedelics, anti-inflammatory effects, systematic review, serotonergic psychedelics, preclinical models, human trials, immunomodulation, cytokines, clinical trial design, translational researchhttps://mindmedicinelaw.com/briefing/rapid-acting-and-neuromodulatory-ocd-treatments-psilocybin-and-beyond-20260928-45585The Psychedelic Journalen2026-09-30T22:06:12.692672+00:00Rapid-Acting and Neuromodulatory OCD Treatments: Psilocybin and Beyondpsilocybin, ketamine, treatment-resistant ocd, neuromodulation, rTMS, deep brain stimulation, stress pathways, clinical trials, regulatory status, biomarkershttps://mindmedicinelaw.com/briefing/persistent-perceptual-abnormalities-in-psychedelic-users-new-insights-from-senso-20260928-45552The Psychedelic Journalen2026-09-30T22:05:56.984922+00:00Persistent Perceptual Abnormalities in Psychedelic Users: New Insights from Sensory Processing Researchpersistent perceptual abnormalities, psychedelic research, sensory processing, conditioned hallucinations, clinical trial risk, public health policy, decision precision, visual discrimination, psilocybin, LSDhttps://mindmedicinelaw.com/briefing/post-psychedelic-difficulties-meta-aggregation-insights-for-counselling-practice-20260927-45287The Psychedelic Journalen2026-09-29T22:04:52.131766+00:00Post-Psychedelic Difficulties: Meta-Aggregation Insights for Counselling Practicepost-psychedelic difficulties, harm reduction, counselling practice, integration support, non-clinical psychedelic use, meta-aggregation, user experiences, public health policy, psychological distress, pluralistic approacheshttps://mindmedicinelaw.com/briefing/cyp2d6-inhibition-and-ibogaine-screening-gaps-in-us-military-health-policy-20260926-45774The Psychedelic Journalen2026-10-01T15:07:07.398780+00:00CYP2D6 Inhibition and Ibogaine: Screening Gaps in US Military Health Policycyp2d6 inhibition, ibogaine therapy, military health system, pharmacogenomics, psychedelic screening, drug-drug interactions, clinical trial design, precision medicine, adverse events, policy developmenthttps://mindmedicinelaw.com/briefing/network-analysis-of-ketamine-in-trd-pooled-rct-insights-2026-20260926-45338The Psychedelic Journalen2026-09-29T22:05:04.422355+00:00Network Analysis of Ketamine in TRD: Pooled RCT Insights (2026)ketamine, treatment-resistant depression, network analysis, randomized controlled trials, psychedelic research, symptom-level outcomes, precision psychiatry, clinical trial design, depression symptom networkshttps://mindmedicinelaw.com/briefing/ketamine-symptom-level-efficacy-in-trd-pooled-rct-analysis-20260926-45395The Psychedelic Journalen2026-09-29T22:04:26.931089+00:00Ketamine Symptom-Level Efficacy in TRD: Pooled RCT Analysisketamine, treatment-resistant depression, symptom-level analysis, randomized controlled trials, network analysis, psychiatric policy, regulatory implications, clinical trial design, personalized psychiatryhttps://mindmedicinelaw.com/briefing/filament-health-expands-psilocybin-supply-for-italian-trd-trial-20260925-45661The Psychedelic Journalen2026-09-30T22:06:38.374656+00:00Filament Health Expands Psilocybin Supply for Italian TRD Trialfilament health, psilocybin, treatment-resistant depression, italy, clinical trials, gmp supply, tempo trial, european regulation, pharma-academic partnershiphttps://mindmedicinelaw.com/briefing/early-data-from-uk-s-first-pediatric-ketamine-uropathy-clinic-20260922-45483The Psychedelic Journalen2026-09-30T15:05:32.932803+00:00Early Data from UK’s First Pediatric Ketamine Uropathy Clinicketamine-induced uropathy, pediatric substance misuse, uk public health, youth drug trends, clinical guidelines, recreational ketamine, sociodemographic risk factors, policy response, harm reduction, adolescent healthhttps://mindmedicinelaw.com/briefing/patient-factors-and-subanesthetic-ketamine-in-pacu-clinical-insights-20260922-45074The Psychedelic Journalen2026-09-30T15:05:18.945170+00:00Patient Factors and Subanesthetic Ketamine in PACU: Clinical Insightssubanesthetic ketamine, postanesthesia care unit, perioperative pain management, patient selection, risk stratification, psychiatric comorbidity, opioid tolerance, clinical protocols, pharmacovigilancehttps://mindmedicinelaw.com/briefing/debate-over-subjective-measures-in-ketamine-and-psilocybin-trials-20260922-44734The Psychedelic Journalen2026-09-30T15:05:07.286684+00:00Debate Over Subjective Measures in Ketamine and Psilocybin Trialssubjective effects, ketamine, psilocybin, clinical trials, measurement tools, meta-analysis, regulatory science, psychotherapy, FDA, methodological rigorhttps://mindmedicinelaw.com/briefing/methodological-critique-of-ketamine-subjective-effects-studies-20260922-44735The Psychedelic Journalen2026-09-30T15:04:55.987731+00:00Methodological Critique of Ketamine Subjective Effects Studiesketamine, subjective effects, methodological flaws, psychedelic-assisted therapy, clinical trial design, meta-analysis, research standards, FDA, validated measures, regulatory implicationshttps://mindmedicinelaw.com/briefing/comorbidity-of-bipolar-disorder-in-cluster-headache-clinical-and-research-implic-20260922-44736The Psychedelic Journalen2026-09-30T15:04:43.690143+00:00Comorbidity of Bipolar Disorder in Cluster Headache: Clinical and Research Implications (Netherlands, 2026)cluster headache, bipolar disorder, comorbidity, psychedelic clinical trials, psychiatric screening, familial aggregation, illicit drug use, patient selection, netherlands, circadian rhythmhttps://mindmedicinelaw.com/briefing/ptsd-fear-circuit-insights-implications-for-psychedelic-interventions-20260922-44745The Psychedelic Journalen2026-09-29T22:06:21.361275+00:00PTSD Fear Circuit Insights: Implications for Psychedelic Interventionsptsd neural circuitry, fear circuit, exposure therapy, propranolol, psychedelic-assisted therapy, mdma, psilocybin, treatment gaps, biomarkers, clinical trial designhttps://mindmedicinelaw.com/briefing/psilocybin-ethocybin-heighten-aversive-memory-in-stressed-mice-20260922-44764The Psychedelic Journalen2026-09-29T22:06:09.017008+00:00Psilocybin, Ethocybin Heighten Aversive Memory in Stressed Micepsilocybin, ethocybin, aversive memory, preclinical study, chronic social stress, pavlovian conditioning, psychedelic therapy, emotional processing, clinical trial risk, neuroplasticityhttps://mindmedicinelaw.com/briefing/glutamatergic-mechanisms-in-depression-schizophrenia-and-addiction-implications--20260922-44767The Psychedelic Journalen2026-09-29T22:05:57.086489+00:00Glutamatergic Mechanisms in Depression, Schizophrenia, and Addiction: Implications for Psychedelic Researchglutamate, psychedelics, depression, schizophrenia, addiction, biomarkers, clinical trial design, ketamine, translational neurosciencehttps://mindmedicinelaw.com/briefing/self-inquiry-as-a-neurophenomenological-tool-implications-for-psychedelic-resear-20260922-44733The Psychedelic Journalen2026-09-29T22:05:42.194572+00:00Self-Inquiry as a Neurophenomenological Tool: Implications for Psychedelic Researchself-inquiry, consciousness research, neurophenomenology, psychedelic therapy, nondual awareness, minimal self, clinical trials, advaita vedanta, subjective experiencehttps://mindmedicinelaw.com/briefing/dmt-harmine-eeg-signatures-implications-for-psychedelic-biomarkers-20260922-44829The Psychedelic Journalen2026-09-29T22:05:28.959464+00:00DMT/Harmine EEG Signatures: Implications for Psychedelic Biomarkersdmt, harmine, eeg biomarkers, psychedelic research, clinical trial design, regulatory science, ayahuasca, neurophysiology, biomarker developmenthttps://mindmedicinelaw.com/briefing/phenomenological-frameworks-in-psychedelic-therapy-implications-for-research-and-20260921-44741The Psychedelic Journalen2026-09-30T15:06:17.868736+00:00Phenomenological Frameworks in Psychedelic Therapy: Implications for Research and Ethicsphenomenology, psychedelic therapy, merleau-ponty, mystical experience, embodiment, clinical trial design, ethics, depression, subjective experience, regulatory policyhttps://mindmedicinelaw.com/briefing/serotonin-1b-receptor-new-target-in-depression-anxiety-research-20260921-44830The Psychedelic Journalen2026-09-30T15:06:04.770646+00:00Serotonin 1B Receptor: New Target in Depression & Anxiety Researchserotonin 1b receptor, depression treatment, anxiety therapy, psychedelic research, serotonergic pathways, clinical trials, drug development, mental health policy, regulatory sciencehttps://mindmedicinelaw.com/briefing/timing-deficits-in-schizophrenia-neurobiological-insights-and-psychedelic-resear-20260921-44738The Psychedelic Journalen2026-09-30T15:05:47.518340+00:00Timing Deficits in Schizophrenia: Neurobiological Insights and Psychedelic Research Implicationsschizophrenia, time processing, dopaminergic dysfunction, gabaergic system, nmda receptor, psychedelic research, biomarkers, clinical trials, cognitive symptoms, neurobiologyhttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-gaba-and-glutamate-in-depression-meta-analysis-insights-20260921-45356The Psychedelic Journalen2026-09-29T22:05:17.527724+00:00Ketamine’s Impact on GABA and Glutamate in Depression: Meta-Analysis Insightsketamine, depression, gaba, glutamate, magnetic resonance spectroscopy, biomarkers, rapid-acting antidepressants, clinical trials, fda regulation, psychiatric drug developmenthttps://mindmedicinelaw.com/briefing/chrysin-as-a-neuroprotective-adjunct-in-ketamine-therapy-implications-for-clinic-20260919-45071The Psychedelic Journalen2026-10-01T15:08:04.578697+00:00Chrysin as a Neuroprotective Adjunct in Ketamine Therapy: Implications for Clinical Usechrysin, ketamine neurotoxicity, neuroprotection, oxidative stress, neuroinflammation, clinical adjuncts, psychedelic safety, preclinical research, policy implicationshttps://mindmedicinelaw.com/briefing/ayahuasca-and-early-life-stress-preclinical-insights-for-neuroscience-and-policy-20260919-44832The Psychedelic Journalen2026-09-30T15:06:29.249826+00:00Ayahuasca and Early-Life Stress: Preclinical Insights for Neuroscience and Policyayahuasca, early-life stress, preclinical research, psychedelic neuroscience, rat model, behavioral outcomes, neurochemical effects, clinical trial design, policy implications, translational challengeshttps://mindmedicinelaw.com/briefing/employment-risks-in-psychedelic-research-policy-and-ethics-in-focus-20260918-44796The Psychedelic Journalen2026-10-01T15:08:21.651449+00:00Employment Risks in Psychedelic Research: Policy and Ethics in Focuspsychedelic research, employment risks, drug testing, clinical trial ethics, informed consent, policy protections, discrimination, institutional review boards, participant safeguardshttps://mindmedicinelaw.com/briefing/framework-for-defining-dmt-assisted-therapy-in-clinical-trials-20260917-44900The Psychedelic Journalen2026-10-01T15:08:36.052823+00:00Framework for Defining DMT-Assisted Therapy in Clinical Trialsdmt-assisted therapy, psychedelic clinical trials, intervention standardization, regulatory pathways, set and setting, integration protocols, methodological rigor, fda approval, efficacy trials